ALKS - Alkermes PLC Stock Price, Fair Value and News

27.86USD-0.18 (-0.64%)Market Closed

Market Summary

USD27.86-0.18

Market Closed

-0.64%

ALKS Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)

ALKS Stock Price

View Fullscreen

ALKS RSI Chart

ALKS Valuation

Market Cap

4.6B

Price/Earnings (Trailing)

16.01

Price/Sales (Trailing)

3.06

EV/EBITDA

9.7

Price/Free Cashflow

14.13

ALKS Price/Sales (Trailing)

ALKS Profitability

EBT Margin

24.87%

Return on Equity

22.49%

Return on Assets

13.08%

Free Cashflow Yield

7.08%

ALKS Fundamentals

ALKS Revenue

Revenue (TTM)

1.5B

Rev. Growth (Yr)

-35.35%

Rev. Growth (Qtr)

13.92%

ALKS Earnings

Earnings (TTM)

288.7M

Earnings Growth (Yr)

-61.46%

Earnings Growth (Qtr)

148.07%

Breaking Down ALKS Revenue

Last 7 days

13.7%

Last 30 days

15.9%

Last 90 days

13.6%

Trailing 12 Months

-6.7%

How does ALKS drawdown profile look like?

ALKS Financial Health

Current Ratio

2.99

Debt/Equity

0.22

Debt/Cashflow

1.31

ALKS Investor Care

Buy Backs (1Y)

0.37%

Diluted EPS (TTM)

1.71

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.7B	1.5B	0	0
2023	1.1B	1.5B	1.6B	1.7B
2022	1.2B	1.2B	1.1B	1.1B
2021	1.0B	1.1B	1.1B	1.2B
2020	1.2B	1.2B	1.2B	1.0B
2019	1.1B	1.1B	1.1B	1.2B
2018	936.7M	1.0B	1.1B	1.1B
2017	780.7M	804.4M	841.5M	903.4M
2016	623.9M	667.7M	695.3M	745.7M
2015	649.8M	647.7M	640.4M	628.3M
2014	563.1M	577.9M	598.1M	618.8M
2013	575.5M	561.9M	577.8M	596.3M
2012	390.0M	480.3M	532.3M	542.6M
2011	186.6M	219.3M	242.1M	331.8M
2010	178.3M	0	181.1M	183.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Alkermes PLC

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

CEO	Mr. Richard F. Pops
WEBSITE	alkermes.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	2280

Alkermes PLC Frequently Asked Questions

What is the ticker symbol for Alkermes PLC? What does ALKS stand for in stocks?

ALKS is the stock ticker symbol of Alkermes PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alkermes PLC (ALKS)?

As of Thu Jul 25 2024, market cap of Alkermes PLC is 4.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALKS stock?

You can check ALKS's fair value in chart for subscribers.

Is Alkermes PLC a good stock to buy?

The fair value guage provides a quick view whether ALKS is over valued or under valued. Whether Alkermes PLC is cheap or expensive depends on the assumptions which impact Alkermes PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALKS.

What is Alkermes PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, ALKS's PE ratio (Price to Earnings) is 14.27 and Price to Sales (PS) ratio is 2.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALKS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alkermes PLC's stock?

In the past 10 years, Alkermes PLC has provided -0.044 (multiply by 100 for percentage) rate of return.